Company overview
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing XENE with another company.
| Daily close (USD) | $36.16 |
| Market capitalization (USD) | $3,501,750,021.12 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.82 |
No matching rows. Clear the filter to see all records.
Read XENE's valuation metrics
Company size
Xenon Pharmaceuticals Inc's recorded market capitalization is $3,501,750,021.12. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
XENE's recorded price-to-book ratio is 2.82. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Xenon Pharmaceuticals Inc with Aurora
Use the snapshot above to ask a specific question about XENE. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow XENE's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.